Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015

Imagem de Miniatura
Arquivos
art_BARBER_Healthcare_Access_and_Quality_Index_based_on_mortality_2017.PDF (28.67 MB)
Citações na Scopus
454
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
BARBER, Ryan M.
FULLMAN, Nancy
SORENSEN, Reed J. D.
BOLLYKY, Thomas
MCKEE, Martin
NOLTE, Ellen
ABAJOBIR, Amanuel Alemu
ABATE, Kalkidan Hassen
ABBAFATI, Cristiana
ABBAS, Kaja M.
Citação
LANCET, v.390, n.10091, p.231-266, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background National levels of personal health-care access and quality can be approximated by measuring mortality rates from causes that should not be fatal in the presence of effective medical care (ie, amenable mortality). Previous analyses of mortality amenable to health care only focused on high-income countries and faced several methodological challenges. In the present analysis, we use the highly standardised cause of death and risk factor estimates generated through the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to improve and expand the quantification of personal health-care access and quality for 195 countries and territories from 1990 to 2015. Methods We mapped the most widely used list of causes amenable to personal health care developed by Nolte and McKee to 32 GBD causes. We accounted for variations in cause of death certification and misclassifications through the extensive data standardisation processes and redistribution algorithms developed for GBD. To isolate the effects of personal health-care access and quality, we risk-standardised cause-specific mortality rates for each geography-year by removing the joint effects of local environmental and behavioural risks, and adding back the global levels of risk exposure as estimated for GBD 2015. We employed principal component analysis to create a single, interpretable summary measure-the Healthcare Quality and Access (HAQ) Index-on a scale of 0 to 100. The HAQ Index showed strong convergence validity as compared with other health-system indicators, including health expenditure per capita (r= 0.88), an index of 11 universal health coverage interventions (r= 0.83), and human resources for health per 1000 (r= 0.77). We used free disposal hull analysis with bootstrapping to produce a frontier based on the relationship between the HAQ Index and the Socio-demographic Index (SDI), a measure of overall development consisting of income per capita, average years of education, and total fertility rates. This frontier allowed us to better quantify the maximum levels of personal health-care access and quality achieved across the development spectrum, and pinpoint geographies where gaps between observed and potential levels have narrowed or widened over time. Findings Between 1990 and 2015, nearly all countries and territories saw their HAQ Index values improve; nonetheless, the difference between the highest and lowest observed HAQ Index was larger in 2015 than in 1990, ranging from 28.6 to 94.6. Of 195 geographies, 167 had statistically significant increases in HAQ Index levels since 1990, with South Korea, Turkey, Peru, China, and the Maldives recording among the largest gains by 2015. Performance on the HAQ Index and individual causes showed distinct patterns by region and level of development, yet substantial heterogeneities emerged for several causes, including cancers in highest-SDI countries; chronic kidney disease, diabetes, diarrhoeal diseases, and lower respiratory infections among middle-SDI countries; and measles and tetanus among lowest-SDI countries. While the global HAQ Index average rose from 40.7 (95% uncertainty interval, 39.0-42.8) in 1990 to 53.7 (52.2-55.4) in 2015, far less progress occurred in narrowing the gap between observed HAQ Index values and maximum levels achieved; at the global level, the difference between the observed and frontier HAQ Index only decreased from 21.2 in 1990 to 20.1 in 2015. If every country and territory had achieved the highest observed HAQ Index by their corresponding level of SDI, the global average would have been 73.8 in 2015. Several countries, particularly in eastern and western sub-Saharan Africa, reached HAQ Index values similar to or beyond their development levels, whereas others, namely in southern sub-Saharan Africa, the Middle East, and south Asia, lagged behind what geographies of similar development attained between 1990 and 2015. Interpretation This novel extension of the GBD Study shows the untapped potential for personal health-care access and quality improvement across the development spectrum. Amid substantive advances in personal health care at the national level, heterogeneous patterns for individual causes in given countries or territories suggest that few places have consistently achieved optimal health-care access and quality across health-system functions and therapeutic areas. This is especially evident in middle-SDI countries, many of which have recently undergone or are currently experiencing epidemiological transitions. The HAQ Index, if paired with other measures of health-systemcharacteristics such as intervention coverage, could provide a robust avenue for tracking progress on universal health coverage and identifying local priorities for strengthening personal health-care quality and access throughout the world.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21245
Referências
  1. Adam T, 2005, BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107
  2. Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207
  3. Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006
  4. Bogetoft P, 2013, BENCHMARKING DATA EN
  5. Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217
  6. Burki TK, 2016, LANCET ONCOL, V17, pE185, DOI 10.1016/S1470-2045(16)30059-6
  7. CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016
  8. Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1
  9. Carmines E. G., 1979, RELIABILITY VALIDITY
  10. CHARLTON JRH, 1986, BRIT MED J, V292, P295
  11. Dye C, 2000, INT J EPIDEMIOL, V29, P558, DOI 10.1093/ije/29.3.558
  12. Ebrahim S, 1999, STROKE EPIDEMIOLOGY
  13. Endreseth BH, 2006, COLORECTAL DIS, V8, P471, DOI 10.1111/j.1463-1318.2005.00921.x
  14. Forouzanfar MH, 2016, LANCET, V388, P1659
  15. Forouzanfar MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2
  16. Gay JG, 2011, MORTALITY AMENABLE H
  17. Group I. A. S., 2004, LANCET, V363, P9
  18. Halstead S, 1985, GOOD HLTH LOW COST
  19. Harris A. R., 2002, HOMICIDE STUDIES, V6, P128, DOI 10.1177/1088767902006002003
  20. Holland W., 1990, INT J QUAL HEALTH C, V2, P227
  21. HOLLAND WW, 1986, HEALTH POLICY, V6, P115, DOI 10.1016/0168-8510(86)90001-1
  22. Hwang S-N, 2016, HDB OPERATIONS ANAL
  23. IAEG-SDGs, 2016, EC SOC COUNC
  24. Illich I., 1975, MED NEMESIS APPROPRI
  25. International Labour Organization, 2010, WORLD SOC SEC REP 20
  26. Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4
  27. Kassebaum NJ, 2016, LANCET, V388, P1603
  28. KELSON M, 1987, INT J EPIDEMIOL, V16, P411, DOI 10.1093/ije/16.3.411
  29. KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441
  30. Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9
  31. Lim SS, 2016, LANCET, V388, P1813, DOI 10.1016/S0140-6736(16)31467-2
  32. Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
  33. Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
  34. Mackenbach JP, 2013, EUR J PUBLIC HEALTH, V23, P195, DOI 10.1093/eurpub/cks192
  35. Mackenbach JP, 1996, J CLIN EPIDEMIOL, V49, P1207, DOI 10.1016/S0895-4356(96)00200-4
  36. MACKENBACH JP, 1988, SOC SCI MED, V27, P889, DOI 10.1016/0277-9536(88)90278-X
  37. MACKENBACH JP, 1991, HEALTH POLICY, V19, P245, DOI 10.1016/0168-8510(91)90011-L
  38. MACKENBACH JP, 1988, J EPIDEMIOL COMMUN H, V42, P325, DOI 10.1136/jech.42.4.325
  39. Manuel DG, 2002, AM J PUBLIC HEALTH, V92, P1481, DOI 10.2105/AJPH.92.9.1481
  40. McCarthy D, 2015, AIMING HIGHER RESULT
  41. McKee M, 2011, HLTH SYSTEMS LOW MID
  42. McKee M, 2010, HEALTH POLICY PLANN, V25, P346, DOI 10.1093/heapol/czq032
  43. McKeown T., 1979, ROLE MED DREAM MIRAG
  44. MCKINLAY JB, 1977, MILBANK FUND Q, V55, P405, DOI 10.2307/3349539
  45. Merali HS, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-280
  46. Modig K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064928
  47. Morris S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4757
  48. Murray CJL, 1999, EPIDEMIOLOGY, V10, P594, DOI 10.1097/00001648-199909000-00029
  49. Naghavi M, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-9
  50. Niti M, 2001, INT J EPIDEMIOL, V30, P966, DOI 10.1093/ije/30.5.966
  51. Nolte E, 2006, DIABETES CARE, V29, P1007, DOI 10.2337/dc05-1550
  52. Nolte E, 2003, BRIT MED J, V327, P1129, DOI 10.1136/bmj.327.7424.1129
  53. Nolte E, 2002, SOC SCI MED, V55, P1905, DOI 10.1016/S0277-9536(01)00320-3
  54. Nolte E., 2004, DOES HEALTHCARE SAVE
  55. Nolte E, 2008, HEALTH AFFAIR, V27, P58, DOI 10.1377/hlthaff.27.1.58
  56. Nolte E, 2012, HEALTH AFFAIR, V31, P2114, DOI 10.1377/hlthaff.2011.0851
  57. Nolte E, 2011, HEALTH POLICY, V103, P47, DOI 10.1016/j.healthpol.2011.08.002
  58. OECD, 2016, HLTH GLANC EUR 2016
  59. PAMPALON R, 1993, SOC SCI MED, V37, P823, DOI 10.1016/0277-9536(93)90376-F
  60. Petrie D, 2014, B WORLD HEALTH ORGAN, V92, P396, DOI 10.2471/BLT.13.132480
  61. The Primary Health Care Performance Initiative (PHCPI), 2015, COV IND 0917
  62. POIKOLAINEN K, 1988, INT J EPIDEMIOL, V17, P86, DOI 10.1093/ije/17.1.86
  63. Richards MA, 2000, BRIT MED J, V320, P895, DOI 10.1136/bmj.320.7239.895
  64. Risso-Gill I, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0916-y
  65. RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104
  66. RUTSTEIN DD, 1980, NEW ENGL J MED, V302, P1146
  67. Schoen C, 2004, HEALTH AFFAIR, V23, pW4487, DOI 10.1377/hlthaff.W4.487
  68. Smith OK, 2015, GOING UNIVERSAL 24 D
  69. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  70. Stockton D, 1997, BRIT MED J, V314, P472
  71. Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119
  72. Tobias M, 2009, AUST NZ J PUBL HEAL, V33, P70, DOI 10.1111/j.1753-6405.2009.00342.x
  73. Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085
  74. Treurniet HF, 2004, J EPIDEMIOL COMMUN H, V58, P290, DOI 10.1136/jech.2002.006452
  75. UN (United Nations), 2015, TRANSF OUR WORLD 203
  76. Vos T, 2016, LANCET, V388, P1545
  77. Wang HD, 2016, LANCET, V388, P1459
  78. WHO, 2000, HLTH SYST IMPR PERF

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/10